Supernus Pharmaceuticals | SUPN - Assets


Supernus Pharmaceuticals reported $1.4B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Abbott USD 108.25B 968M Sep/2026
ANI Pharmaceuticals USD 1.57B 73.55M Sep/2026
Aurora Cannabis CAD 620.88M 19.79M Jun/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Canopy Growth CAD 1.1B 14.81M Jun/2026
Cara Therapeutics USD 25.82M 6.26M Mar/2026
Corcept Therapeutics USD 1.03B 145.32M Sep/2026
Eisai JPY 1.56T 108.98B Jun/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Novo Nordisk DKK 594.94B 35.72B Jun/2026
Pacira USD 34.68B 33.44B Sep/2026
Perrigo USD 7.48B 124.6M Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Supernus Pharmaceuticals USD 1.4B 30.42M Sep/2026
United Therapeutics USD 7.03B 186M Sep/2026
Xeris Pharmaceuticals USD 423.22M 11.31M Sep/2026